Actuate Therapeutics, Inc. (ACTU) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "ACTU"
      ],
      "issuer_cik": "0001652935",
      "owner_cik": "0001318470",
      "accession_number": "0001683168-26-008147",
      "form_type": "4",
      "filing_date": "2026-10-29",
      "period_of_report": "2026-10-28",
      "issuer_name": "ACTUATE THERAPEUTICS, INC.",
      "issuer_trading_symbol": "ACTU",
      "owner_name": "SCHMITT DANIEL M",
      "is_director": true,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "President, CEO and Director",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-10-28",
      "transaction_code": "P",
      "equity_swap_involved": false,
      "transaction_shares": 140844,
      "transaction_price_per_share": 0.355,
      "transaction_acquired_disposed": "A",
      "shares_owned_following_transaction": 442560,
      "transaction_value": 49999.619999999995,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Represents shares of common stock purchased on October 28, 2026 in connection with Issuers public offering."
        }
      ]
    },
    {
      "tickers": [
        "ACTU"
      ],
      "issuer_cik": "0001652935",
      "owner_cik": "0001696711",
      "accession_number": "0001011438-26-000005",
      "form_type": "4",
      "filing_date": "2026-01-07",
      "period_of_report": "2026-01-05",
      "issuer_name": "ACTUATE THERAPEUTICS, INC.",
      "issuer_trading_symbol": "ACTU",
      "owner_name": "Kairos Venture Partners II, L.P.",
      "is_director": true,
      "is_ten_percent_owner": true,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-01-05",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 280000,
      "transaction_price_per_share": 5.8,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 904795,
      "transaction_value": 1624000,
      "direct_or_indirect": "I",
      "nature_of_ownership": "By Kairos Venture Partners II, L.P.",
      "footnotes": [
        {
          "id": "F1",
          "description": "The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."
        },
        {
          "id": "F2",
          "description": "Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purpose."
        }
      ],
      "remarks": "Todd Thomson serves as CFO/COO of Kairos Venture Investments, LLC and is a director on the board of directors of Actuate Therapeutics, Inc. (\"Actuate\"). Due to their relationship with Todd Thomson, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons other than Todd Thomson are deemed to be directors by deputization of Actuate."
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.